Deal Summary
McColl Partners, LLC served as exclusive financial advisor to Zymed Laboratories, Inc. in its $60 million sale to Invitrogen Corporation (Nasdaq:IVGN), a leading, global life sciences company. Dave Vorhoff and John Fennebresque led McColl Partners’ efforts with regard to this transaction and were supported by David Sheffer and Jessica Somers.

The acquisition provides Invitrogen with more than 2,000 antibodies and related products that match key areas of its research product focus, including cancer, neurological, and infectious diseases. Combining Zymed’s extensive experience in antibody design, development, modification, purification, and production with Invitrogen's broad portfolio of technologies and reagents will provide researchers and clinical laboratories with a consistent, comprehensive system to accelerate scientific discovery.

About Zymed Laboratories, Inc.
Zymed Laboratories, Inc. is an integrated, technology-driven, immunoassay reagent company based in South San Francisco, CA. Zymed serves two primary segments: life sciences research and clinical diagnostics. Zymed has over 21 years of technological expertise in antibody design, development, modification, purification, and production.

About McColl Partners
McColl Partners is an independent investment banking firm specializing in the needs of management and owners of middle-market companies. With significant experience working with entrepreneurs, family-owned businesses, public companies, private equity groups, and divisions of larger companies, the firm is dedicated to offering strategic advice and assistance to its clients regarding mergers and acquisitions and private capital raising assignments.

To learn more about our expertise in the health care industry, please contact
Dave Vorhoff at 704-333-0519. More information about McColl Partners can be found at www.mccollpartners.com.